Host Daniel Litwin on Why Vendors Should Secure DHA/DLA Contracts

When it comes to procurement at the highest level, contracts can become a complicated business. Medical grade equipment for the military always requires next-level due diligence throughout the ordering process and, because of this, procurement can often take months to a year to finalize. With internal solutions like Electronic Catalog (ECAT), there are now ways to not only save money on procurement but also time.

Bob Charron sits down on the with host of the Champions of Care, a podcast to discuss the differences between different major contracts and their solutions such as Defense Health Agency (DHA), Defense Logistics Agency (DLA), and ECAT. He goes in depth on how these solutions streamline processes that once took 60-90 minutes to complete.

The world of procurement is one that leaves no stone unturned to get equipment in the hands of customers and because of that, the process would often take a long time. Charron talks about how this problem with efficiency led to changing how vendors did business. “Initially it all started when we needed some sort of vehicle to procure more efficiently and to get the best possible cost from the vendor community,” he said.

This change in procurement came on the heels of new innovations that made improving old systems far easier. In using new tools and means of communication, solutions like ECAT were able to be born. Charron talks about this change, “We’re seeing as time has evolved, technology has improved, communication has improved, and access to information has improved, I think there’s sort of a move to streamline it further.”

Thanks to solutions like ECAT and new contracts, equipment can get into the hands of customers without a long delay. The process is now also streamlined for easier ordering, using the essential tools to pull off procurement while eliminating the old tools that take up time and money for little to no use.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More